Report Detail
Global Living Biological Drugs Market Growth (Status and Outlook) 2022-2028
- RnM4488262 |
- 29 August, 2022 |
- Global |
- 124 Pages |
- LPI(LP Information) |
- Service & Software
The global market for Living Biological Drugs is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Living Biological Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Living Biological Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Living Biological Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Living Biological Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Living Biological Drugs players cover Ardeypharman, Miyarisan Pharmaceutical, Ferring Pharmaceuticals, Seres Therapeutics and Infant Bacterial Therapeutics, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Living Biological Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Living Biological Drugs market, with both quantitative and qualitative data, to help readers understand how the Living Biological Drugs market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.
Market Segmentation:
The study segments the Living Biological Drugs market and forecasts the market size by Type (Single Strain, Multi Strain and Co-Culture), by Application (Digestive System, Urinary System and Skin System,), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Single Strain
Multi Strain
Co-Culture
Segmentation by application
Digestive System
Urinary System
Skin System
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Ardeypharman
Miyarisan Pharmaceutical
Ferring Pharmaceuticals
Seres Therapeutics
Infant Bacterial Therapeutics
Osel
Takeda
AOBiome
Synlogic
Finch Therapeutics
Capsugel
Jeneil Biotech
UAS Labs
Biose
Cerbios-Pharma
Inpac Probiotics
NIZO
Winclove Probiotics
BJP Laboratories
Luina Bio
List Labs
MatriSys Bioscience
Chapter Introduction
Chapter 1: Scope of Living Biological Drugs, Research Methodology, etc.
Chapter 2: Executive Summary, global Living Biological Drugs market size and CAGR, Living Biological Drugs market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Living Biological Drugs revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Living Biological Drugs revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Living Biological Drugs market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Ardeypharman, Miyarisan Pharmaceutical, Ferring Pharmaceuticals, Seres Therapeutics, Infant Bacterial Therapeutics, Osel, Takeda, AOBiome and Synlogic, etc.
Chapter 14: Research Findings and Conclusion
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Living Biological Drugs Market Size 2017-2028
- 2.1.2 Living Biological Drugs Market Size CAGR by Region 2017 VS 2022 VS 2028
- 2.2 Living Biological Drugs Segment by Type
- 2.2.1 Single Strain
- 2.2.2 Multi Strain
- 2.2.3 Co-Culture
- 2.3 Living Biological Drugs Market Size by Type
- 2.3.1 Living Biological Drugs Market Size CAGR by Type (2017 VS 2022 VS 2028)
- 2.3.2 Global Living Biological Drugs Market Size Market Share by Type (2017-2022)
- 2.4 Living Biological Drugs Segment by Application
- 2.4.1 Digestive System
- 2.4.2 Urinary System
- 2.4.3 Skin System
- 2.5 Living Biological Drugs Market Size by Application
- 2.5.1 Living Biological Drugs Market Size CAGR by Application (2017 VS 2022 VS 2028)
- 2.5.2 Global Living Biological Drugs Market Size Market Share by Application (2017-2022)
3 Living Biological Drugs Market Size by Player
- 3.1 Living Biological Drugs Market Size Market Share by Players
- 3.1.1 Global Living Biological Drugs Revenue by Players (2020-2022)
- 3.1.2 Global Living Biological Drugs Revenue Market Share by Players (2020-2022)
- 3.2 Global Living Biological Drugs Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
4 Living Biological Drugs by Regions
- 4.1 Living Biological Drugs Market Size by Regions (2017-2022)
- 4.2 Americas Living Biological Drugs Market Size Growth (2017-2022)
- 4.3 APAC Living Biological Drugs Market Size Growth (2017-2022)
- 4.4 Europe Living Biological Drugs Market Size Growth (2017-2022)
- 4.5 Middle East & Africa Living Biological Drugs Market Size Growth (2017-2022)
5 Americas
- 5.1 Americas Living Biological Drugs Market Size by Country (2017-2022)
- 5.2 Americas Living Biological Drugs Market Size by Type (2017-2022)
- 5.3 Americas Living Biological Drugs Market Size by Application (2017-2022)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
6 APAC
- 6.1 APAC Living Biological Drugs Market Size by Region (2017-2022)
- 6.2 APAC Living Biological Drugs Market Size by Type (2017-2022)
- 6.3 APAC Living Biological Drugs Market Size by Application (2017-2022)
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
7 Europe
- 7.1 Europe Living Biological Drugs by Country (2017-2022)
- 7.2 Europe Living Biological Drugs Market Size by Type (2017-2022)
- 7.3 Europe Living Biological Drugs Market Size by Application (2017-2022)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
8 Middle East & Africa
- 8.1 Middle East & Africa Living Biological Drugs by Region (2017-2022)
- 8.2 Middle East & Africa Living Biological Drugs Market Size by Type (2017-2022)
- 8.3 Middle East & Africa Living Biological Drugs Market Size by Application (2017-2022)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
10 Global Living Biological Drugs Market Forecast
- 10.1 Global Living Biological Drugs Forecast by Regions (2023-2028)
- 10.1.1 Global Living Biological Drugs Forecast by Regions (2023-2028)
- 10.1.2 Americas Living Biological Drugs Forecast
- 10.1.3 APAC Living Biological Drugs Forecast
- 10.1.4 Europe Living Biological Drugs Forecast
- 10.1.5 Middle East & Africa Living Biological Drugs Forecast
- 10.2 Americas Living Biological Drugs Forecast by Country (2023-2028)
- 10.2.1 United States Living Biological Drugs Market Forecast
- 10.2.2 Canada Living Biological Drugs Market Forecast
- 10.2.3 Mexico Living Biological Drugs Market Forecast
- 10.2.4 Brazil Living Biological Drugs Market Forecast
- 10.3 APAC Living Biological Drugs Forecast by Region (2023-2028)
- 10.3.1 China Living Biological Drugs Market Forecast
- 10.3.2 Japan Living Biological Drugs Market Forecast
- 10.3.3 Korea Living Biological Drugs Market Forecast
- 10.3.4 Southeast Asia Living Biological Drugs Market Forecast
- 10.3.5 India Living Biological Drugs Market Forecast
- 10.3.6 Australia Living Biological Drugs Market Forecast
- 10.4 Europe Living Biological Drugs Forecast by Country (2023-2028)
- 10.4.1 Germany Living Biological Drugs Market Forecast
- 10.4.2 France Living Biological Drugs Market Forecast
- 10.4.3 UK Living Biological Drugs Market Forecast
- 10.4.4 Italy Living Biological Drugs Market Forecast
- 10.4.5 Russia Living Biological Drugs Market Forecast
- 10.5 Middle East & Africa Living Biological Drugs Forecast by Region (2023-2028)
- 10.5.1 Egypt Living Biological Drugs Market Forecast
- 10.5.2 South Africa Living Biological Drugs Market Forecast
- 10.5.3 Israel Living Biological Drugs Market Forecast
- 10.5.4 Turkey Living Biological Drugs Market Forecast
- 10.5.5 GCC Countries Living Biological Drugs Market Forecast
- 10.6 Global Living Biological Drugs Forecast by Type (2023-2028)
- 10.7 Global Living Biological Drugs Forecast by Application (2023-2028)
11 Key Players Analysis
- 11.1 Ardeypharman
- 11.1.1 Ardeypharman Company Information
- 11.1.2 Ardeypharman Living Biological Drugs Product Offered
- 11.1.3 Ardeypharman Living Biological Drugs Revenue, Gross Margin and Market Share (2020-2022)
- 11.1.4 Ardeypharman Main Business Overview
- 11.1.5 Ardeypharman Latest Developments
- 11.2 Miyarisan Pharmaceutical
- 11.2.1 Miyarisan Pharmaceutical Company Information
- 11.2.2 Miyarisan Pharmaceutical Living Biological Drugs Product Offered
- 11.2.3 Miyarisan Pharmaceutical Living Biological Drugs Revenue, Gross Margin and Market Share (2020-2022)
- 11.2.4 Miyarisan Pharmaceutical Main Business Overview
- 11.2.5 Miyarisan Pharmaceutical Latest Developments
- 11.3 Ferring Pharmaceuticals
- 11.3.1 Ferring Pharmaceuticals Company Information
- 11.3.2 Ferring Pharmaceuticals Living Biological Drugs Product Offered
- 11.3.3 Ferring Pharmaceuticals Living Biological Drugs Revenue, Gross Margin and Market Share (2020-2022)
- 11.3.4 Ferring Pharmaceuticals Main Business Overview
- 11.3.5 Ferring Pharmaceuticals Latest Developments
- 11.4 Seres Therapeutics
- 11.4.1 Seres Therapeutics Company Information
- 11.4.2 Seres Therapeutics Living Biological Drugs Product Offered
- 11.4.3 Seres Therapeutics Living Biological Drugs Revenue, Gross Margin and Market Share (2020-2022)
- 11.4.4 Seres Therapeutics Main Business Overview
- 11.4.5 Seres Therapeutics Latest Developments
- 11.5 Infant Bacterial Therapeutics
- 11.5.1 Infant Bacterial Therapeutics Company Information
- 11.5.2 Infant Bacterial Therapeutics Living Biological Drugs Product Offered
- 11.5.3 Infant Bacterial Therapeutics Living Biological Drugs Revenue, Gross Margin and Market Share (2020-2022)
- 11.5.4 Infant Bacterial Therapeutics Main Business Overview
- 11.5.5 Infant Bacterial Therapeutics Latest Developments
- 11.6 Osel
- 11.6.1 Osel Company Information
- 11.6.2 Osel Living Biological Drugs Product Offered
- 11.6.3 Osel Living Biological Drugs Revenue, Gross Margin and Market Share (2020-2022)
- 11.6.4 Osel Main Business Overview
- 11.6.5 Osel Latest Developments
- 11.7 Takeda
- 11.7.1 Takeda Company Information
- 11.7.2 Takeda Living Biological Drugs Product Offered
- 11.7.3 Takeda Living Biological Drugs Revenue, Gross Margin and Market Share (2020-2022)
- 11.7.4 Takeda Main Business Overview
- 11.7.5 Takeda Latest Developments
- 11.8 AOBiome
- 11.8.1 AOBiome Company Information
- 11.8.2 AOBiome Living Biological Drugs Product Offered
- 11.8.3 AOBiome Living Biological Drugs Revenue, Gross Margin and Market Share (2020-2022)
- 11.8.4 AOBiome Main Business Overview
- 11.8.5 AOBiome Latest Developments
- 11.9 Synlogic
- 11.9.1 Synlogic Company Information
- 11.9.2 Synlogic Living Biological Drugs Product Offered
- 11.9.3 Synlogic Living Biological Drugs Revenue, Gross Margin and Market Share (2020-2022)
- 11.9.4 Synlogic Main Business Overview
- 11.9.5 Synlogic Latest Developments
- 11.10 Finch Therapeutics
- 11.10.1 Finch Therapeutics Company Information
- 11.10.2 Finch Therapeutics Living Biological Drugs Product Offered
- 11.10.3 Finch Therapeutics Living Biological Drugs Revenue, Gross Margin and Market Share (2020-2022)
- 11.10.4 Finch Therapeutics Main Business Overview
- 11.10.5 Finch Therapeutics Latest Developments
- 11.11 Capsugel
- 11.11.1 Capsugel Company Information
- 11.11.2 Capsugel Living Biological Drugs Product Offered
- 11.11.3 Capsugel Living Biological Drugs Revenue, Gross Margin and Market Share (2020-2022)
- 11.11.4 Capsugel Main Business Overview
- 11.11.5 Capsugel Latest Developments
- 11.12 Jeneil Biotech
- 11.12.1 Jeneil Biotech Company Information
- 11.12.2 Jeneil Biotech Living Biological Drugs Product Offered
- 11.12.3 Jeneil Biotech Living Biological Drugs Revenue, Gross Margin and Market Share (2020-2022)
- 11.12.4 Jeneil Biotech Main Business Overview
- 11.12.5 Jeneil Biotech Latest Developments
- 11.13 UAS Labs
- 11.13.1 UAS Labs Company Information
- 11.13.2 UAS Labs Living Biological Drugs Product Offered
- 11.13.3 UAS Labs Living Biological Drugs Revenue, Gross Margin and Market Share (2020-2022)
- 11.13.4 UAS Labs Main Business Overview
- 11.13.5 UAS Labs Latest Developments
- 11.14 Biose
- 11.14.1 Biose Company Information
- 11.14.2 Biose Living Biological Drugs Product Offered
- 11.14.3 Biose Living Biological Drugs Revenue, Gross Margin and Market Share (2020-2022)
- 11.14.4 Biose Main Business Overview
- 11.14.5 Biose Latest Developments
- 11.15 Cerbios-Pharma
- 11.15.1 Cerbios-Pharma Company Information
- 11.15.2 Cerbios-Pharma Living Biological Drugs Product Offered
- 11.15.3 Cerbios-Pharma Living Biological Drugs Revenue, Gross Margin and Market Share (2020-2022)
- 11.15.4 Cerbios-Pharma Main Business Overview
- 11.15.5 Cerbios-Pharma Latest Developments
- 11.16 Inpac Probiotics
- 11.16.1 Inpac Probiotics Company Information
- 11.16.2 Inpac Probiotics Living Biological Drugs Product Offered
- 11.16.3 Inpac Probiotics Living Biological Drugs Revenue, Gross Margin and Market Share (2020-2022)
- 11.16.4 Inpac Probiotics Main Business Overview
- 11.16.5 Inpac Probiotics Latest Developments
- 11.17 NIZO
- 11.17.1 NIZO Company Information
- 11.17.2 NIZO Living Biological Drugs Product Offered
- 11.17.3 NIZO Living Biological Drugs Revenue, Gross Margin and Market Share (2020-2022)
- 11.17.4 NIZO Main Business Overview
- 11.17.5 NIZO Latest Developments
- 11.18 Winclove Probiotics
- 11.18.1 Winclove Probiotics Company Information
- 11.18.2 Winclove Probiotics Living Biological Drugs Product Offered
- 11.18.3 Winclove Probiotics Living Biological Drugs Revenue, Gross Margin and Market Share (2020-2022)
- 11.18.4 Winclove Probiotics Main Business Overview
- 11.18.5 Winclove Probiotics Latest Developments
- 11.19 BJP Laboratories
- 11.19.1 BJP Laboratories Company Information
- 11.19.2 BJP Laboratories Living Biological Drugs Product Offered
- 11.19.3 BJP Laboratories Living Biological Drugs Revenue, Gross Margin and Market Share (2020-2022)
- 11.19.4 BJP Laboratories Main Business Overview
- 11.19.5 BJP Laboratories Latest Developments
- 11.20 Luina Bio
- 11.20.1 Luina Bio Company Information
- 11.20.2 Luina Bio Living Biological Drugs Product Offered
- 11.20.3 Luina Bio Living Biological Drugs Revenue, Gross Margin and Market Share (2020-2022)
- 11.20.4 Luina Bio Main Business Overview
- 11.20.5 Luina Bio Latest Developments
- 11.21 List Labs
- 11.21.1 List Labs Company Information
- 11.21.2 List Labs Living Biological Drugs Product Offered
- 11.21.3 List Labs Living Biological Drugs Revenue, Gross Margin and Market Share (2020-2022)
- 11.21.4 List Labs Main Business Overview
- 11.21.5 List Labs Latest Developments
- 11.22 MatriSys Bioscience
- 11.22.1 MatriSys Bioscience Company Information
- 11.22.2 MatriSys Bioscience Living Biological Drugs Product Offered
- 11.22.3 MatriSys Bioscience Living Biological Drugs Revenue, Gross Margin and Market Share (2020-2022)
- 11.22.4 MatriSys Bioscience Main Business Overview
- 11.22.5 MatriSys Bioscience Latest Developments
12 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Living Biological Drugs. Industry analysis & Market Report on Living Biological Drugs is a syndicated market report, published as Global Living Biological Drugs Market Growth (Status and Outlook) 2022-2028. It is complete Research Study and Industry Analysis of Living Biological Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
